Kiora Pharmaceuticals与CKD达成独家许可协议：KIO-301韩国眼科权益授予

美股速递

Aug 19

Kiora Pharmaceuticals（纳斯达克代码：KPRX）近日通过美国证券交易委员会（SEC）文件披露，公司已向CKD授予KIO-301在韩国市场的独家许可权，用于眼科领域。

这一战略举措意味着，韩国市场将迎来KIO-301的本地化开发与商业化推进。根据协议内容，CKD将全权负责该候选药物在韩国境内的相关事务，涵盖临床开发、监管申报及上市推广等环节。

KIO-301是Kiora Pharmaceuticals的核心在研管线资产，其针对眼科适应症的潜力正逐步获得业界认可。此番与CKD的合作，不仅拓宽了该药物的地理覆盖版图，也体现了Kiora在亚太地区布局上的审慎考量。

从交易结构来看，该协议赋予CKD排他性权利，但具体财务条款——诸如首付款、里程碑付款及销售分成等细节——暂未在文件中完全披露。市场观察人士指出，此类区域性授权交易通常能为授权方带来可观的非稀释性融资，同时降低自建海外团队的成本与风险。

Kiora Pharmaceuticals管理层在提交的文件中强调，此次合作符合公司聚焦核心治疗领域、依托合作伙伴网络实现全球化价值释放的长期战略。受此消息影响，投资者情绪或将对KPRX股价产生短线波动，但长期价值仍需观察后续临床数据及销售表现。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1188868041"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188868041\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188868041?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-08-19 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188868041","market":"us","top_or_hot":-1,"title":"Kiora Pharmaceuticals与CKD达成独家许可协议：KIO-301韩国眼科权益授予","media":"美股速递","content":"<p>Kiora Pharmaceuticals（纳斯达克代码：KPRX）近日通过美国证券交易委员会（SEC）文件披露，公司已向CKD授予KIO-301在韩国市场的独家许可权，用于眼科领域。</p>\n<p>这一战略举措意味着，韩国市场将迎来KIO-301的本地化开发与商业化推进。根据协议内容，CKD将全权负责该候选药物在韩国境内的相关事务，涵盖临床开发、监管申报及上市推广等环节。</p>\n<p>KIO-301是Kiora Pharmaceuticals的核心在研管线资产，其针对眼科适应症的潜力正逐步获得业界认可。此番与CKD的合作，不仅拓宽了该药物的地理覆盖版图，也体现了Kiora在亚太地区布局上的审慎考量。</p>\n<p>从交易结构来看，该协议赋予CKD排他性权利，但具体财务条款——诸如首付款、里程碑付款及销售分成等细节——暂未在文件中完全披露。市场观察人士指出，此类区域性授权交易通常能为授权方带来可观的非稀释性融资，同时降低自建海外团队的成本与风险。</p>\n<p>Kiora Pharmaceuticals管理层在提交的文件中强调，此次合作符合公司聚焦核心治疗领域、依托合作伙伴网络实现全球化价值释放的长期战略。受此消息影响，投资者情绪或将对KPRX股价产生短线波动，但长期价值仍需观察后续临床数据及销售表现。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kiora Pharmaceuticals与CKD达成独家许可协议：KIO-301韩国眼科权益授予</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKiora Pharmaceuticals与CKD达成独家许可协议：KIO-301韩国眼科权益授予\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-08-19 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kiora Pharmaceuticals（纳斯达克代码：KPRX）近日通过美国证券交易委员会（SEC）文件披露，公司已向CKD授予KIO-301在韩国市场的独家许可权，用于眼科领域。</p>\n<p>这一战略举措意味着，韩国市场将迎来KIO-301的本地化开发与商业化推进。根据协议内容，CKD将全权负责该候选药物在韩国境内的相关事务，涵盖临床开发、监管申报及上市推广等环节。</p>\n<p>KIO-301是Kiora Pharmaceuticals的核心在研管线资产，其针对眼科适应症的潜力正逐步获得业界认可。此番与CKD的合作，不仅拓宽了该药物的地理覆盖版图，也体现了Kiora在亚太地区布局上的审慎考量。</p>\n<p>从交易结构来看，该协议赋予CKD排他性权利，但具体财务条款——诸如首付款、里程碑付款及销售分成等细节——暂未在文件中完全披露。市场观察人士指出，此类区域性授权交易通常能为授权方带来可观的非稀释性融资，同时降低自建海外团队的成本与风险。</p>\n<p>Kiora Pharmaceuticals管理层在提交的文件中强调，此次合作符合公司聚焦核心治疗领域、依托合作伙伴网络实现全球化价值释放的长期战略。受此消息影响，投资者情绪或将对KPRX股价产生短线波动，但长期价值仍需观察后续临床数据及销售表现。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KPRX","symbol_name":"Kiora Pharmaceuticals","start_time":0,"source_url":"","article_id":"1188868041","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188868041","pubTimestamp":1787137394,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Kiora Pharmaceuticals近日通过美国证券交易委员会文件披露，公司已向CKD授予KIO-301在韩国市场的独家许可权，用于眼科领域。这一战略举措意味着，韩国市场将迎来KIO-301的本地化开发与商业化推进。KIO-301是Kiora Pharmaceuticals的核心在研管线资产，其针对眼科适应症的潜力正逐步获得业界认可。Kiora Pharmaceuticals管理层在提交的文件中强调，此次合作符合公司聚焦核心治疗领域、依托合作伙伴网络实现全球化价值释放的长期战略。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"KPRX":"Kiora Pharmaceuticals","BK4007":"制药"},"translate_title":"Kiora Pharmaceuticals and CKD Reach Exclusive License Agreement: KIO-301 Korean Ophthalmic Rights Grant","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KPRX":1},"content_text":"Kiora Pharmaceuticals（纳斯达克代码：KPRX）近日通过美国证券交易委员会（SEC）文件披露，公司已向CKD授予KIO-301在韩国市场的独家许可权，用于眼科领域。\n这一战略举措意味着，韩国市场将迎来KIO-301的本地化开发与商业化推进。根据协议内容，CKD将全权负责该候选药物在韩国境内的相关事务，涵盖临床开发、监管申报及上市推广等环节。\nKIO-301是Kiora Pharmaceuticals的核心在研管线资产，其针对眼科适应症的潜力正逐步获得业界认可。此番与CKD的合作，不仅拓宽了该药物的地理覆盖版图，也体现了Kiora在亚太地区布局上的审慎考量。\n从交易结构来看，该协议赋予CKD排他性权利，但具体财务条款——诸如首付款、里程碑付款及销售分成等细节——暂未在文件中完全披露。市场观察人士指出，此类区域性授权交易通常能为授权方带来可观的非稀释性融资，同时降低自建海外团队的成本与风险。\nKiora Pharmaceuticals管理层在提交的文件中强调，此次合作符合公司聚焦核心治疗领域、依托合作伙伴网络实现全球化价值释放的长期战略。受此消息影响，投资者情绪或将对KPRX股价产生短线波动，但长期价值仍需观察后续临床数据及销售表现。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}